Clinical Trials

184 enrolled

Phase 1 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04794699 2026-04-09

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

169 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms

NCT05382299 2026-04-06

ASCENT-03

623 enrolled

Triple Negative Breast Neoplasms

NCT04039230 2026-03-16

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

75 enrolled

Breast Neoplasms

NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

70 enrolled

Urothelial Bladder Carcinoma

NCT06028932 2026-03-05

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

20 enrolled

Gynecologic

Ovarian Neoplasms

NCT06100874 2026-02-24

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

28 enrolled

Breast Neoplasms

NCT06178588 2026-02-24

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

15 enrolled

Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

NCT04251416 2026-02-17

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

50 enrolled

Gynecologic

Endometrial Neoplasms

NCT05186974 2026-02-11

EVOKE-02

193 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04639986 2026-02-09

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

331 enrolled

Breast Neoplasms

NCT04454437 2026-02-02

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

80 enrolled

Triple Negative Breast Neoplasms

NCT03964727 2026-01-30

TROPiCS-03

223 enrolled 31 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT05327530 2026-01-26

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

256 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04448886 2026-01-15

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

110 enrolled 26 charts

Breast Neoplasms

NCT06486441 2026-01-15

ASCENT-GYN-01

640 enrolled

Gynecologic

Endometrial Neoplasms

NCT05609968 2025-12-24

MK-3475-D46

614 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04863885 2025-12-17

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

46 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06612203 2025-12-05

WIN-B

76 enrolled

Advanced Breast Cancer

NCT04595565 2025-11-25

SASCIA

1,332 enrolled

Triple Negative Breast Neoplasms

NCT05119907 2025-11-17

Study of Sacituzumab Govitecan in Patients With Solid Tumor

53 enrolled

Other solid neoplasm

Solid Tumor

NCT05675579 2025-11-04

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

27 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT05143229 2025-10-06

ASSET

18 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05840211 2025-10-03

ASCENT-07

654 enrolled

Breast Neoplasms

NCT05382286 2025-09-18

ASCENT-04

443 enrolled

Triple Negative Breast Neoplasms

NCT05089734 2025-05-23

EVOKE-01

603 enrolled 20 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03725761 2025-05-13

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

31 enrolled 12 charts

Prostatic Neoplasms

NCT04647916 2025-04-24

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

44 enrolled

CNS

Brain Neoplasms

NCT05101096 2025-03-25

ASCENT-J02

135 enrolled